TRPC6 and breast cancer: Given that women with breast cancer are commonly treated with doxorubicin and that our initial genetic studies identified TRPC6 genetic variants as associated with a decline in LVEF in women with breast cancer (19), in this study we also assessed female mice treated with the same dose of doxorubicin as the dose given to males.